Media
Back
With a total funding of HK$5.07 million, the project aims to define the bioactive components of Shenmai injection and their mechanisms of action. Shenmai injection is a product manufactured by Chiatai Qingchunbao Pharmaceutical Co. Ltd., in Hangzhou. (Chiatai Qingchunbao Pharmaceutical Co is a subsidiary of SIIC Medical Science and Technology (Group) Limited.) Clinically used in the mainland for heart disease as well as a supplement for cancer therapy, sales of this product reached 14.6 million vials in 2001.
Dr Siow Yaw-Loong and Dr O Karmin from HKU's Department of Pharmacology will team up with Professor Zhu Da-Yuan of Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Science, to add scientific value to the product and help increase its quality to an international standard. The HKU team will focus on the elucidation of the biological mechanisms of Chinese medicinal compounds isolated form Shenmai injection, while the SIMM team will focus on the isolation and structural characterization of these compounds.
The project is a prime example of the investment from the Hong Kong private sector into research and development for Chinese medicine utilizing the knowledge and resources of HKU. It also meets the aim of the Innovative and Technology Commission to establish a global credibility for the development of health food and pharmaceuticals based on Chinese medicine.
For media enquiries, please contact Miss Polo Leung at HKU's External Relations Office (tel: 2859 2600) or Miss Wendy Chan at SIIC Medical Science and Technology (Group) Limited (tel: 2876 2310).
SIIC MEDTECH and HKU awarded innovation and technology fund to produce an improved Chinese Medicinal Product
03 May 2002
SIIC Medical Science and Technology (Group) Limited (SIIC MedTech) and The University of Hong Kong (HKU) have been awarded a grant from the Innovation and Technology Commission for a university-industry collaborative research project to produce an improved Chinese medicinal product, Shenmai injection. A signing ceremony was held today (May 3rd) to mark the collaboration between HKU and SIIC MedTech. Mr Francis Ho, Commissioner of the Innovation and Technology Commission, also attended the ceremony.
With a total funding of HK$5.07 million, the project aims to define the bioactive components of Shenmai injection and their mechanisms of action. Shenmai injection is a product manufactured by Chiatai Qingchunbao Pharmaceutical Co. Ltd., in Hangzhou. (Chiatai Qingchunbao Pharmaceutical Co is a subsidiary of SIIC Medical Science and Technology (Group) Limited.) Clinically used in the mainland for heart disease as well as a supplement for cancer therapy, sales of this product reached 14.6 million vials in 2001.
Dr Siow Yaw-Loong and Dr O Karmin from HKU's Department of Pharmacology will team up with Professor Zhu Da-Yuan of Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Science, to add scientific value to the product and help increase its quality to an international standard. The HKU team will focus on the elucidation of the biological mechanisms of Chinese medicinal compounds isolated form Shenmai injection, while the SIMM team will focus on the isolation and structural characterization of these compounds.
The project is a prime example of the investment from the Hong Kong private sector into research and development for Chinese medicine utilizing the knowledge and resources of HKU. It also meets the aim of the Innovative and Technology Commission to establish a global credibility for the development of health food and pharmaceuticals based on Chinese medicine.
For media enquiries, please contact Miss Polo Leung at HKU's External Relations Office (tel: 2859 2600) or Miss Wendy Chan at SIIC Medical Science and Technology (Group) Limited (tel: 2876 2310).
Facebook 
HKU IOS App 
HKU Android App 
Social Media and Apps